Background: The outlook on “Nano-materials, products, medicine and technology”
lacks a consensus on the definition to be considered by regulatory bodies all over the world. Engineered
nanoparticles, the formulated products containing nanomaterials, are not subject to any
precise regulation pertaining to production, handling and labeling till now. Also, nano medicines
holding an immense potential involved in treatment and diagnosis with emerging research, yet, lag
behind with unnoticed concerns regarding their safety and toxicity. Therefore, a regulatory
framework focused on specific guidelines for products with the application of nanotechnology is
being designed for extending the immense benefits of nanomedicines to humanity. Regulatory
bodies have taken the forefront in dealing with the risks associated with nanomedicines, including
the United States Environment Protection Agency (EPA) and the US Food and Drug Administration
(USFDA), and the Health and Consumer Protection Directorate of the European Commission
Objective: The study aimed to depict the current status and suggest future perspectives of nanomedicine,
by compiling the guidance of different regulatory bodies, thereby, eliminating the
vagueness of nanotechnology in regulatory terms.
Conclusion: Ambiguity continues to prevail considering the regulations and safety of nanomaterials.
Therefore, it becomes vital to facilitate the harmonization of assessment practices for nanomaterials
with a unanimous opinion. On global level, OECD and its Working Party are currently
dealing with manufactured nanomaterials.